OBJECTIVE: To investigate the clinical application of Paclitaxel for injection（albumin-bound） for cancer therapy in a hospital

and to provide reference for rational drug use. METHODS: The use of Paclitaxel for injection（albumin-bound） in medical orders of discharged patients in a hospital from 2020 to 2021 was retrospectively analyzed by using PASS PharmAssist. According to Chinese drug instructions

US Food and Drug Administration approved instructions

the recommendations of US National Comprehensive Cancer Network Clinical Practice Guidelines and Chinese Society of Clinical Oncology Diagnosis and Treatment Guidelines

the treatment of patients was analyzed and evaluated. RESULTS: A total of 329 patients used Paclitaxel for injection（albumin-bound） 1 091 times

227 cases（69.00%） were in accordance with the indications and the recommendations of guidelines and expert consensus

and there were irrational drug use. The main adverse drug reactions of Paclitaxel for injection（albumin-bound） were hematological toxicity

gastrointestinal reactions

peripheral nervous system reactions

skin and liver injuries. CONCLUSIONS: The unreasonable use of Paclitaxel for injection（albumin-bound） in clinical practice in our hospital is mainly manifested in over-indication drug use

leapfrog use

unsuitable usage and dosage

unsuitable solvent and infusion time

inappropriate combination of drugs

etc. Clinicians should strictly grasp the drug instructions and refer to the corresponding guidelines for the use of Paclitaxel for injection（albumin-bound）

use drug combination rationally

strengthen the management and monitoring of adverse drug reactions

and ensure safe drug use.